相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Blockage of Stat3 enhances the sensitivity of NSCLC cells to PI3K/mTOR inhibition
Hyeon-Ok Jin et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)
A meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with non-small-cell lung cancer
Y. H. Xu et al.
EJSO (2014)
Disruption of STAT3 by Niclosamide Reverses Radioresistance of Human Lung Cancer
Shuo You et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model
Toshi Murakami et al.
LUNG CANCER (2014)
STAT3 upregulates miR-92a to inhibit RECK expression and to promote invasiveness of lung cancer cells
H-Y Lin et al.
BRITISH JOURNAL OF CANCER (2013)
OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells
Mi-Jung Kim et al.
CANCER LETTERS (2013)
Protective effects of ADAM8 against cisplatin-mediated apoptosis in non-small-cell lung cancer
Weifeng Zhang et al.
CELL BIOLOGY INTERNATIONAL (2013)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
Silencing of the transcription factor STAT3 sensitizes lung cancer cells to DNA damaging drugs, but not to TNFα- and NK cytotoxicity
Dorota W. Kulesza et al.
EXPERIMENTAL CELL RESEARCH (2013)
Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non-Small Cell Lung Cancer
Rui Li et al.
MOLECULAR CANCER THERAPEUTICS (2013)
MECHANISMS OF DISEASE JAKs and STATs in Immunity, Immunodeficiency, and Cancer
John J. O'Shea et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
MicroRNA 96 Is a Post-Transcriptional Suppressor of Anaplastic Lymphoma Kinase Expression
Deeksha Vishwamitra et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation
Daijiro Harada et al.
CANCER SCIENCE (2012)
JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease
John J. O'Shea et al.
IMMUNITY (2012)
PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells
Wen-Pin Su et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2012)
Activation of IL-6R/JAK1/STAT3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Non-Small Cell Lung Cancer with T790M Resistance Mutation
Sun Mi Kim et al.
MOLECULAR CANCER THERAPEUTICS (2012)
STAT3 Is Activated by JAK2 Independent of Key Oncogenic Driver Mutations in Non-Small Cell Lung Carcinoma
Brendan D. Looyenga et al.
PLOS ONE (2012)
miR-337-3p and Its Targets STAT3 and RAP1A Modulate Taxane Sensitivity in Non-Small Cell Lung Cancers
Liqin Du et al.
PLOS ONE (2012)
First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy
Malabika Sen et al.
CANCER DISCOVERY (2012)
Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells
Huan-Chih Chiu et al.
BIOCHEMICAL PHARMACOLOGY (2011)
Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer
Marina Lesina et al.
CANCER CELL (2011)
STAT3 Mediates Resistance to MEK Inhibitor through MicroRNA miR-17
Bingbing Dai et al.
CANCER RESEARCH (2011)
Discovery of 5 Chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a Novel Inhibitor of the Jak/Stat Pathway
Stephanos Ioannidis et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Inhibition of JAK2 Signaling by TG101209 Enhances Radiotherapy in Lung Cancer Models
Yunguang Sun et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
JAK1 Activates STAT3 Activity in Non-Small-Cell Lung Cancer Cells and IL-6 Neutralizing Antibodies Can Suppress JAK1-STAT3 Signaling
Lanxi Song et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Correlation of Activated STAT3 Expression with Clinicopathologic Features in Lung Adenocarcinoma and Squamous Cell Carcinoma
Richeng Jiang et al.
MOLECULAR DIAGNOSIS & THERAPY (2011)
JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer
Mei Zhao et al.
LUNG CANCER (2011)
STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma
A. Horiguchi et al.
BRITISH JOURNAL OF CANCER (2010)
Pharmacokinetic and Pharmacodynamic Modeling of an Anti-Interleukin-6 Chimeric Monoclonal Antibody (Siltuximab) in Patients with Metastatic Renal Cell Carcinoma
Thomas Puchalski et al.
CLINICAL CANCER RESEARCH (2010)
Growth inhibition of human ovarian cancer cells by blocking STAT3 activation with small interfering RNA
Liying Cai et al.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY (2010)
HCMV-Encoded Chemokine Receptor US28 Mediates Proliferative Signaling Through the IL-6-STAT3 Axis
Erik Slinger et al.
SCIENCE SIGNALING (2010)
Regulation of the IL-23 and IL-12 Balance by Stat3 Signaling in the Tumor Microenvironment
Marcin Kortylewski et al.
CANCER CELL (2009)
The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors
Michael Hedvat et al.
CANCER CELL (2009)
gp130-Mediated Stat3 Activation in Enterocytes Regulates Cell Survival and Cell-Cycle Progression during Colitis-Associated Tumorigenesis
Julia Bollrath et al.
CANCER CELL (2009)
IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated Cancer
Sergei Grivennikov et al.
CANCER CELL (2009)
Sustained Src Inhibition Results in Signal Transducer and Activator of Transcription 3 (STAT3) Activation and Cancer Cell Survival via Altered Janus-Activated Kinase-STAT3 Binding
Banibrata Sen et al.
CANCER RESEARCH (2009)
Interleukin-6 in the Bone Marrow Microenvironment Promotes the Growth and Survival of Neuroblastoma Cells
Tasnim Ara et al.
CANCER RESEARCH (2009)
β1 Integrin Adhesion Enhances IL-6-Mediated STAT3 Signaling in Myeloma Cells: Implications for Microenvironment Influence on Tumor Survival and Proliferation
Kenneth H. Shain et al.
CANCER RESEARCH (2009)
Reciprocal Regulation of c-Src and STAT3 in Non-Small Cell Lung Cancer
Lauren Averett Byers et al.
CLINICAL CANCER RESEARCH (2009)
Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling
Sebastian Zimmer et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2009)
IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway
Lin Wang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Therapeutic potential of JAK2 inhibitors
S. Verstovsek
Hematology-American Society of Hematology Education Program (2009)
Environment-mediated drug resistance: a major contributor to minimal residual disease
Mark B. Meads et al.
NATURE REVIEWS CANCER (2009)
Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice
Maciej Kujawski et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Cancer-related inflammation
Alberto Mantovani et al.
NATURE (2008)
Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer
Tetsuya Mitsudomi et al.
CANCER SCIENCE (2007)
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas
Sizhi Paul Gao et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Activation of the signal transducers and activators of the transcription 3 pathway in alveolar epithelial cells induces inflammation and adenocarcinomas in mouse lung
Yuan Li et al.
CANCER RESEARCH (2007)
Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice
Xulong Zhang et al.
BMC CANCER (2007)
The STAT3 oncogene as a predictive marker of drug resistance
Benjamin Barre et al.
TRENDS IN MOLECULAR MEDICINE (2007)
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations
Akira Inoue et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor
JV Alvarez et al.
CANCER RESEARCH (2006)
Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer
EB Haura et al.
CLINICAL CANCER RESEARCH (2005)
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants
H Greulich et al.
PLOS MEDICINE (2005)
Erlotinib in lung cancer - Molecular and clinical predictors of outcome
MS Tsao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Signal transducer and activator of transcription 3 is a key regulator of keratinocyte survival and proliferation following UV irradiation
S Sano et al.
CANCER RESEARCH (2005)
Molecular therapy to inhibit NFκB activation by transcription factor decoy oligonucleotides
R Morishita et al.
CURRENT OPINION IN PHARMACOLOGY (2004)
The stats of cancer - New molecular targets come of age
H Yu et al.
NATURE REVIEWS CANCER (2004)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways
R Sordella et al.
SCIENCE (2004)
Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells
YS Pu et al.
PROSTATE (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer
J Mendelsohn et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells
LX Song et al.
ONCOGENE (2003)
Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth
PL Leong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Opposite regulation of Myc and p21waf1 transcription by STAT3 proteins
B Barré et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells
M Huang et al.
ONCOGENE (2002)
Roles of activated Src and Stat3 signaling in melanoma tumor cell growth
G Niu et al.
ONCOGENE (2002)
STATs: Transcriptional control and biological impact
DE Levy et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2002)
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
I Vivanco et al.
NATURE REVIEWS CANCER (2002)
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo
M Levis et al.
BLOOD (2002)
Transcriptional stimulation of the surfactant protein B gene by STAT3 in respiratory epithelial cells
C Yan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells
WM Burke et al.
ONCOGENE (2001)
Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells
R Garcia et al.
ONCOGENE (2001)
Co-operative effect of c-Src tyrosine kinase and Stat3 in activation of hepatocyte growth factor expression in mammary carcinoma cells
W Hung et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Serine phosphorylation of STATs
T Decker et al.
ONCOGENE (2000)
分享论文
